Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

Conclusion: Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.PMID:37606897 | DOI:10.57264/cer-2022-0175

Source: Journal of Comparative Effectiveness Research - August 22, 2023 Category: General Medicine Authors: Virender Bhan Fraser Clift Moogeh Baharnoori Kimberly Thomas Barkha P Patel Fran çois Blanchette Nicholas Adlard Umakanth Vudumula Kapil Gudala Nikkita Dutta Daniel Grima Souka ïna Mouallif Fatine Farhane Source Type: research